StemExpress was founded in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. StemExpress supports cell and gene therapies, commercialization of disease specific treatments, medical research, clinical trials, precision/regenerative medicine, among other researchers and clinicians around the world who are developing and implementing revolutionary treatments and cures. StemExpress is currently the nation's leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. StemExpress is registered with the U.S. Food and Drug Administration (FDA) and has seven (7) independently owned and operated brick-and mortar cellular clinics across the United States to collect blood, cells and tissue from patients and donors. These clinics include state-of-the-art cell manufacturing laboratories for clinical and research purposes, and CLIA certified/high-complexity diagnostics. #celltherapy #genetherapy #primarycells #immunotherapy #immunology #cancerresearch #biotechnology #biospecimens #cancerresearch #biomedicalresearch #stemcellresearch #covidtesting
Looking for a particular StemExpress employee's phone or email?
The StemExpress annual revenue was $28.1 million in 2026.
8 people are employed at StemExpress.
StemExpress is based in Folsom, California.
The NAICS codes for StemExpress are [541, 54171, 5417, 54, 541711].
The SIC codes for StemExpress are [87, 873].